Glenmark Pharma arm files papers for IPO with Sebi

-

 


Glenmark Pharma arm files papers for IPO with Sebi

 

Glenmark Pharmaceuticals on Saturday said its wholly-owned arm Glenmark Life Sciences has filed preliminary papers for an initial public offer with market regulator Sebi.

 

Glenmark Life Sciences has filed a Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (Sebi) for an initial public offer, according to a regulatory filing.

 

The offer comprises fresh issue of up to Rs 1,160 crore and an offer for sale of up to 73,05,245 equity shares of Rs 2 each of Glenmark Life Sciences Ltd, by Glenmark Pharmaceuticals Ltd, the filing said.

 

The board of directors of Glenmark Pharmaceuticals Ltd during its meeting on April 16 approved the offer for sale of up to 73,05,245 equity shares of Rs 2 apiece as part of the IPO.

 

The IPO will be subject to market conditions, receipt of applicable approvals and other considerations, the filing said.

Comments

Post a Comment

Popular posts from this blog

Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy

-
  Indegene acquires Trilogy Writing & Consulting GmbH,  a medical writing consultancy   India, March 27, 2024:  Indegene, a  digital-first, life sciences commercialization company , announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies. The acquisition by Indegene Ireland, a subsidiary of Indegene Limited, augments Indegene’s depth of clinical and regulatory writing expertise for market authorization applications globally.   Trilogy Writing & Consulting is a Germany, UK, and US-based, medical writing consultancy with know-how in the development and delivery of clinical, regulatory, safety, and medical content. It applies its expertise and unique approaches to deliver quality medical writing output. Trilogy has a proven track record of more than 22 years of providing medical writing services to the biopharmaceutica
Read more

TiEcon Mumbai 2023, brilliantly showcased revolutionary ideas & impactful solutions to build an Anti-Fragile and Sustainable India

-
Image
TiEcon Mumbai 2023, brilliantly showcased revolutionary ideas & impactful solutions to build an Anti-Fragile and Sustainable India Mumbai, 09 June 2023 : The 16th Edition of TiEcon Mumbai, organised by TiE Mumbai at Jio Convention Centre, BKC culminated on an enthusiastic note with a call to build an Anti-Fragile and Sustainable India. It kick-started with marquee speakers focusing on ways to accelerate growth, drive more intelligent engagement, make conscious choices and methods to empower sustainable business building ideas. Speaking at the summit, Ranu Vohra, President- TiE Mumbai said, “It was great to see the energy of the startup eco system at work at TiECon 2023. There were lively debates on Mumbai’s roadmap to becoming the startup hub, Gen AI and its role in India and the opportunities, thus created. The session on funding availability held out promise that as the startups become “anti-fragile” and focus on unit economics and profitability we should see a renewed incre
Read more

REC DECLARES ITS FINANCIAL RESULTS FOR Q2 & H1 FY24

-
REC DECLARES ITS FINANCIAL RESULTS FOR Q2 & H1 FY24   REC RECORDS ITS HIGHEST EVER QUARTERLY PROFIT AT ₹3,773 CRORE Mumbai/New Delhi, November 01, 2023: REC limited, a ‘Maharatna’ company under the administrative control of the Ministry of Power, Government of India, and registered with RBI as Non-Banking Finance Company (NBFC), Public Financial Institution (PFI) and Infrastructure Financing Company (IFC), has today reported its unaudited financial results (Standalone) for the 2nd Quarter and Half Year ended 30th September 2023. Key highlights are as under:  Operational and Financial Highlights –Q2 FY24 vs Q2 FY23 (Standalone) • Sanctions: ₹ 1,04,366 crore vs. ₹ 84,889 crore, up 23%, Renewable sector constitutes for 24% • Disbursements: ₹ 41,598 crore vs. ₹ 17,827 crore, up 133% • Interest Income on Loan Assets: ₹ 11,213 crore vs. ₹ 9,534 crore, up 18% • Net Profit: ₹ 3,773 crore vs. ₹ 2,728 crore, up 38% • Total Comprehensive Income: ₹ 4,188 crore vs. ₹ 1,915 crore, up 1
Read more